Melero-Martin Lab - Research

LIke ThisLIke ThisLIke ThisLIke ThisLIke This


Endothelial Colony-Forming Cells (ECFCs)

ECFCs are progenitors of endothelial cells that circulate in peripheral blood. ECFCs have enormous potential in Regenerative Medicine because they can generate large amounts of autologous ECs for vascular therapies. We specialize in the biology of human ECFCs derived from umbilical cord blood and adult peripheral blood. We are currently studying several aspects of ECFCs:

  • Phenotypical and functional properties of ECFCs
  • Methods for ECFC isolation
  • ECFC levels in health and disease
  • Therapeutic potential of ECFCs

Key publications


Human white adipose tissue vasculature contains endothelial colony-forming cells with robust in vivo vasculogenic potential. Lin RZ*, Moreno-Luna R*, Muñoz-Hernandez R, Li D, Jaminet SC, Greene AK, Melero-Martin JM. Angiogenesis 2013; 34(28):6785-96. PDF

In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S, Bischoff J. Blood 2007; 109:4761-4768. PDF


-----


Bioengineering Vascular Networks 

Vascular networks are central to the functioning of most tissue. We use a two-cell approach to bioengineer human vascular networks in vivo. In our model, human blood-derived ECFCs are combined with human Mesenchymal Stem Cells (MSCs) in a biocompatible hydrogel and injected subcutaneously into immunodeficient mice where they form an organized vascular network that joins with the mouse vasculature. This model is ideally suited for studies on the cellular and molecular mechanisms of human vascular network formation and for developing strategies to vascularize tissues. VIDEO

Key publications


Transdermal regulation of vascular network bioengineering using a photopolymerizable methacrylated gelatin hydrogel. Lin RZ, Chen YC, Moreno-Luna R, Khademhosseini A, Melero-Martin JM.  Biomaterials 2013; 34(28):6785-96. PDF

Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Melero-Martin JM, De Obaldia ME, Kang S-Y, Khan ZA, Yuan L, Oettgen P, Bischoff J. Circ Res 2008; 103:194-202. PDF


----- 


Genetically-Engineered Vasculature for Protein Drug Delivery

The ability to bioengineer vasculature creates the possibility to introduce additional instructions into tissues by genetically modifying the endothelial cells that will actually build these blood vessels. We are developing models that use genetically-engineered ECFCs to achieve controlled administration of therapeutic proteins in vivo.

Key publications

Induction of erythropoiesis using human vascular networks genetically-engineered for controlled erythropoietin release. Lin RZ, Dreyzin A, Aamodt K, Li D, Jaminet SCS, Dudley AC, Melero-Martin JM.  Blood 2011; 118(20):5420-8. PDF
Request an Appointment

If this is a medical emergency, please dial 9-1-1. This form should not be used in an emergency.

Patient Information
Date of Birth:
Contact Information
Appointment Details
Send RequestIf you do not see the specialty you are looking for, please call us at: 617-355-6000.International visitors should call International Health Services at +1-617-355-5209.
Please complete all required fieldsThis department is currently not accepting appointment requests onlineThis department is currently not accepting appointment requests online

Thank you.

Your request has been successfully submitted

You will be contacted within 1 business day.

If you have questions or would like more information, please call:

617-355-6000 +1-617-355-6000
close
Find a Doctor
Search by Clinician's Last Name or Specialty:
Select by Location:
Search by First Letter of Clinician's Last Name: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
More optionsSearch
Condition & Treatments
Search for a Condition or Treatment:
Show Items Starting With: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
View allSearch
Visitor Information
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO
Close